Clinical relevance of host immunity in breast cancer: from TILs to the clinic

被引:686
作者
Savas, Peter [1 ]
Salgado, Roberto [2 ]
Denkert, Carsten [3 ,4 ]
Sotiriou, Christos [2 ]
Darcy, Phillip K. [1 ]
Smyth, Mark J. [5 ]
Loi, Sherene [1 ]
机构
[1] Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, East Melbourne, Vic 8006, Australia
[2] Inst Jules Bordet, Breast Canc Translat Res Lab, Blvd Waterloo 121, B-1000 Brussels, Belgium
[3] Charite, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany
[4] German Canc Consortium DKTK, Charitepl 1, D-10117 Berlin, Germany
[5] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld 4006, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; MHC CLASS-I; NEOADJUVANT CHEMOTHERAPY; T-CELLS; ANTITUMOR IMMUNITY; PREDICT RESPONSE; CLONAL EXPANSION; AUTOLOGOUS TUMOR; PD-1; BLOCKADE;
D O I
10.1038/nrclinonc.2015.215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical relevance of the host immune system in breast cancer has long been unexplored. Studies developed over the past decade have highlighted the biological heterogeneity of breast cancer, prompting researchers to investigate whether the role of the immune system in this malignancy is similar across different molecular subtypes of the disease. The presence of high levels of lymphocytic infiltration has been consistently associated with a more-favourable prognosis in patients with early stage triple-negative and HER2-positive breast cancer. These infiltrates seem to reflect favourable host antitumour immune responses, suggesting that immune activation is important for improving survival outcomes. In this Review, we discuss the composition of the immune infiltrates observed in breast cancers, as well as data supporting the clinical relevance of host antitumour immunity, as represented by lymphocytic infiltration, and how this biomarker could be used in the clinical setting. We also discuss the rationale for enhancing immunity in breast cancer, including early data on the efficacy of T-cell checkpoint inhibition in this setting.
引用
收藏
页码:228 / 241
页数:14
相关论文
共 125 条
[1]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[2]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[3]   Immunity, inflammation and cancer: a leading role for adenosine [J].
Antonioli, Luca ;
Blandizzi, Corrado ;
Pacher, Pal ;
Hasko, Gyoergy .
NATURE REVIEWS CANCER, 2013, 13 (12) :842-857
[4]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[5]  
BAXEVANIS CN, 1994, CANCER, V74, P1275, DOI 10.1002/1097-0142(19940815)74:4<1275::AID-CNCR2820740416>3.0.CO
[6]  
2-Q
[7]   Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses [J].
Beavis, Paul A. ;
Milenkovski, Nicole ;
Henderson, Melissa A. ;
John, Liza B. ;
Allard, Bertrand ;
Loi, Sherene ;
Kershaw, Michael H. ;
Stagg, John ;
Darcy, Phillip K. .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) :506-517
[8]   Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors [J].
Beavis, Paul A. ;
Divisekera, Upulie ;
Paget, Christophe ;
Chow, Melvyn T. ;
John, Liza B. ;
Devaud, Christel ;
Dwyer, Karen ;
Stagg, John ;
Smyth, Mark J. ;
Darcy, Phillip K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (36) :14711-14716
[9]  
Brown M, 2000, CLIN CHEM, V46, P1221
[10]  
CHIN Y, 1992, ANTICANCER RES, V12, P1463